Michele Milella
Overview
Explore the profile of Michele Milella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
384
Citations
10636
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fiorini E, Malinova A, Schreyer D, Pasini D, Bevere M, Alessio G, et al.
Nature
. 2025 Mar;
PMID: 40074906
Intratumour heterogeneity and phenotypic plasticity drive tumour progression and therapy resistance. Oncogene dosage variation contributes to cell-state transitions and phenotypic heterogeneity, thereby providing a substrate for somatic evolution. Nonetheless, the...
2.
Borsati A, Ciurnelli C, Belluomini L, Sposito M, Insolda J, Toniolo L, et al.
Heliyon
. 2025 Mar;
11(4):e42768.
PMID: 40066037
A 55-year-old female patient affected by an EGFR mutant NSCLC with multiple lytic bone metastases and two prior pathological fractures, undergoing treatment with osimertinib and denosumab, participated in a 9-month...
3.
Zacchi F, Sordo A, Torresan I, Lorenzi C, Tasselli E, Pafumi S, et al.
Front Oncol
. 2025 Mar;
15:1532421.
PMID: 40061901
Introduction And Objectives: Patients (pts) with metastatic urothelial carcinoma (mUC) gain substantial benefit from immunotherapy exposure. If they do not experience disease progression after 4-6 cycles of first-line platinum-based chemotherapy...
4.
Fiala O, Buti S, Fujita K, de Liano A, Fukuokaya W, Kimura T, et al.
Clin Exp Metastasis
. 2025 Feb;
42(2):18.
PMID: 39976819
Patients with metastatic urothelial carcinoma (mUC) are typically elderly and often have other comorbidities that require the use of concomitant medications. In our study we evaluated the association of concomitant...
5.
Avancini A, Trestini I, Belluomini L, Milella M, Pilotto S
Expert Rev Anticancer Ther
. 2025 Feb;
:1-4.
PMID: 39968945
No abstract available.
6.
Mastrantoni L, Garufi G, Giordano G, Maliziola N, Di Monte E, Arcuri G, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):11.
PMID: 39910103
Hormone receptor-positive/HER2-negative breast cancer (BC) is the most common subtype of BC and typically occurs as an early, operable disease. In patients receiving neoadjuvant chemotherapy (NACT), pathological complete response (pCR)...
7.
Borsati A, Giannarelli D, Pase G, Ciurnelli C, Toniolo L, Trestini I, et al.
Front Oncol
. 2025 Jan;
14:1430083.
PMID: 39871943
Introduction: We aim to examine the population's perception of physical exercise in patients with cancer. Materials And Methods: An anonymous survey was conducted to reach a sample of Italian adults....
8.
Milella M, Orsi G, di Marco M, Salvatore L, Procaccio L, Noventa S, et al.
Cancer Med
. 2025 Jan;
14(3):e70364.
PMID: 39861955
Introduction: Pancreatic cancer arising in the context of BRCA predisposition may benefit from poly(ADP-ribose) polymerase inhibitors. We analyzed real-world data on the impact of olaparib on survival in metastatic pancreatic...
9.
Rossi A, Zacchi F, Reni A, Rota M, Palmerio S, Menis J, et al.
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39519290
Epigenetic dysregulation has long been recognized as a significant contributor to tumorigenesis and tumor maintenance, impacting all recognized cancer hallmarks. Although some epigenetic drugs have received regulatory approval for certain...
10.
Trestini I, Belluomini L, Dodi A, Sposito M, Caldart A, Kadrija D, et al.
J Cachexia Sarcopenia Muscle
. 2024 Oct;
15(6):2349-2360.
PMID: 39439222
Background: While immune checkpoint inhibitors (ICIs) are increasingly reshaping the therapeutic landscape of non-small-cell lung cancer (NSCLC), only a limited proportion of patients achieve a relevant and long-lasting benefit with...